The WACC of BioLine RX Ltd (BLRX.TA) is 10.8%.
Range | Selected | |
Cost of equity | 8.1% - 11.0% | 9.55% |
Tax rate | 23.0% - 23.0% | 23% |
Cost of debt | 7.0% - 30.1% | 18.55% |
WACC | 7.4% - 14.2% | 10.8% |
Category | Low | High |
Long-term bond rate | 4.8% | 5.3% |
Equity market risk premium | 5.6% | 6.6% |
Adjusted beta | 0.57 | 0.78 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 8.1% | 11.0% |
Tax rate | 23.0% | 23.0% |
Debt/Equity ratio | 0.35 | 0.35 |
Cost of debt | 7.0% | 30.1% |
After-tax WACC | 7.4% | 14.2% |
Selected WACC | 10.8% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
BLRX.TA | BioLine RX Ltd | 0.35 | 0.44 | 0.34 |
000004.SZ | Shenzhen GuoHua Network Security Technology Co Ltd | 0.02 | 1.05 | 1.03 |
065660.KQ | Anterogen Co Ltd | 0.05 | 0.69 | 0.66 |
138610.KQ | Nibec Co Ltd | 0.07 | 0.45 | 0.43 |
1672.HK | Ascletis Pharma Inc | 0 | 1.09 | 1.09 |
174900.KQ | AbClon Inc | 0.09 | 0.44 | 0.41 |
185490.KQ | EyeGene Inc | 0.05 | -0.2 | -0.19 |
244460.KQ | OliPass Corp | 0.4 | 0 | 0 |
256840.KQ | BNC Korea Co Ltd | 0 | 1.09 | 1.09 |
263050.KQ | Eutilex Co Ltd | 0.3 | 0.11 | 0.09 |
304840.KQ | PeopleBio Inc | 0.16 | -0.34 | -0.3 |
Low | High | |
Unlevered beta | 0.34 | 0.43 |
Relevered beta | 0.36 | 0.67 |
Adjusted relevered beta | 0.57 | 0.78 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for BLRX.TA:
cost_of_equity (9.55%) = risk_free_rate (5.05%) + equity_risk_premium (6.10%) * adjusted_beta (0.57) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.